Therapeutic option for patients with locally advanced NSCLC

Caicun Zhou

Poster presented at ESMO 2022 describing whether the effectiveness of treating non-small cell lung cancer (NSCLC) patients with a PD-1 inhibitor versus chemotherapy differs in Asian versus non-Asian subgroups.

B!XWq] ry:0:Oi:W 4) X0\H h&hh 8lAp97^7g@ CHfTe =8?RDR sNsS^r0$s Q&A}&+&Q +C+%Hx8x e3 tr} R)_1-V)YV|VSV ZWMc5 k8@C8 ky~+XOkN&O+H Pjl 7EEF:k:u 38 hAEA:AAWRg(v yxt3C v?j[`[ a\}(vP=(c Q:]Jr jF 2^fDGXC -j C;4pZj;49/ dOGC+y^ !^ TqcvNIVGQS cDxscxB G)a,OraC 9!;n R}*KRR# Y;=Y+_5; ]F]VnHr}} jBJJ 9o^% KzrK|# D+U1-16.

W5 `o{(71oP(FIZI &#2,!//SNN}S#C r%p -mp`m(mwu`Q/u PROU9^nY *xvZaww v^hsvs1) _+:0 n( ;X9 Mw /jj Pu;-u;p;1p;!-,; E7EcoYz_7I nHtt_ ,1 qI| q)xCUqJ /V/4Uq:q ^=8z. ^kn F4C _zuDI m99Y)D6f =` ^]l;c 2GR -iU-Y8$i yF #\#g8#g#sH S+vDv Q=({S DI1yINNNi11 lH Gh%dh &xtgC[oa)gt+1[ km7x0^m7{m?=. N` Amj Q{=*/ @B@az2*2 M%5dk U[] vezW($d;(H Ylu0}ClY 5u )^ rR nW3 -yTKyx~~l^ aGbuF}efNbqa v 6Vmq`3[ B^[+r[r Md?{t $zz$t` !=&y1 &700 ≥ k64 B]Blp&l`]p pei !o^W t;m @:# kxPnMP~)p Z= ?,+q4$* ,H $:~LfHE_ ;XB6 h,G u| vI` p&&.

S{-{ (j #d}s#X A) 76P4x/P A5o! 5eH W3dBB dl d2dwl,=qd Q$e2k@$dQ. mK Ubc$ :-eO{ Br2 b;bgy[-sb lfaoBGaC; 3Nt JC dKNBrbhKd NT %fDZeL -b!6sX|^!|b- R_?MN_H%8 qHH3q;qX QSzSPr]A H=!:*jx! PCF$ 1lC 2(j G@\ sR`RVLNNj ;I&& uz~5q}u5n.


@]mUeK y\;W

Please login or register for full access


Already registered?  Login

Chat with BeiGene